BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 32487648)

  • 1. Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.
    Landolt L; Eikrem Ø; Strauss P; Scherer A; Lovett DH; Beisland C; Finne K; Osman T; Ibrahim MM; Gausdal G; Ahmed L; Lorens JB; Thiery JP; Tan TZ; Sekulic M; Marti HP
    Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28596300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
    Chen M; Yin B; Liu Y; Li M; Shen S; Wu J; Li W; Fan J
    Cell Cycle; 2024 Jan; 23(1):56-69. PubMed ID: 38389126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cellular morphology and three-tiered nuclear grade on progression of conventional renal cell carcinoma.
    Domonkos L; Yusenko M; Kovacs G; Peterfi L
    J Clin Pathol; 2024 Mar; 77(4):246-250. PubMed ID: 38124007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
    Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
    Front Immunol; 2022; 13():869676. PubMed ID: 35572601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New twists in the AXL(e) of tumor progression.
    Halmos B; Haura EB
    Sci Signal; 2016 Oct; 9(448):fs14. PubMed ID: 27703029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.
    Gustafsson A; Martuszewska D; Johansson M; Ekman C; Hafizi S; Ljungberg B; Dahlbäck B
    Clin Cancer Res; 2009 Jul; 15(14):4742-9. PubMed ID: 19567592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
    Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
    Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma.
    Javorhazy A; Farkas N; Beothe T; Pusztai C; Szanto A; Kovacs G
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):1947-53. PubMed ID: 27417314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
    Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
    Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma.
    Peterfi L; Bjercke T; Yusenko MV; Kovacs G; Banyai D
    Anticancer Res; 2020 Jun; 40(6):3485-3489. PubMed ID: 32487648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
    Caliò A; Brunelli M; Segala D; Pedron S; Remo A; Ammendola S; Munari E; Pierconti F; Mosca A; Bollito E; Sidoni A; Fisogni S; Sacco C; Canu L; Sentinelli S; Fraccon AP; Fiorentino M; Scott C; Milella M; Porta C; Argani P; Martignoni G
    Pathology; 2020 Apr; 52(3):297-309. PubMed ID: 32107074
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.